RecruitingNon-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Eligible age
18+ yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Participants must have a histologically or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with Stage IIIB/IIIC or Stage IV disease.
- ✓ Participants must have a programmed death ligand-1 (PD-L1) expression ≥ 50%.
- ✓ Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- ✓ Participants must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.
- ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
You may not qualify if…
- ✕ Participants must not have any documented actionable genomic alteration (AGA) for which first-line (1L) approved therapies are indicated.
- ✕ Participants must not have any symptomatic untreated central nervous system (CNS) metastases, leptomeningeal metastases (carcinomatous meningitis) or spinal cord compression.
- ✕ Participants must not have any significant cardiovascular impairment as evidenced by uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, or major thrombotic or embolic events or major hemorrhagic events (within 6 months prior to randomization), or significant risk of pulmonary hemorrhage.
- ✕ Participants must not an active autoimmune disease.
- ✕ Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's recruiting
Alabama
Daphne
Arizona
Bullhead City · Glendale
California
Beverly Hills · Fountain Valley · Los Alamitos · Los Angeles …
Colorado
Lakewood
Florida
Clermont · Coral Springs · Hialeah · Tamarac
Georgia
Athens · Augusta · Marietta
Illinois
Urbana
Indiana
Dyer
Missouri
Columbia
New York
Laurelton · New York · Westbury
North Carolina
Winston-Salem
Ohio
Cincinnati
Source: ClinicalTrials.gov · NCT07361510 · last updated 2026-10-23